[ Price : $8.95]
FDA removes risk evaluation and mitigation strategies requirements for all currently approved CAR T cell therapies, saying the pro...[ Price : $8.95]
UCB reports positive data from a Phase 3 clinical trial evaluating fenfluramine as an adjunctive treatment for rare epileptic ence...[ Price : $8.95]
An appeals court rules for FDA that a clinically superior drug is not the same as a drug that is otherwise the same.[ Price : $8.95]
Achieve Life Sciences files an NDA for cytisinicline for treating nicotine dependence as part of smoking cessation in adults.[ Price : $8.95]
FDA issues safety-related labeling updates for two bile acid transport inhibitors Mirum Pharmaceuticals Livmarli and Ipsen Biopha...[ Price : $8.95]
FDA publishes a question-and-answer guidance to help sponsors develop new antibacterial drugs.[ Price : $8.95]
Altimmune reports mixed topline results today from its Phase 2b IMPACT trial evaluating pemvidutide in patients with metabolic dys...[ Price : $8.95]
FDA posts a draft guidance entitled Unique Device Identifier (UDI) Requirements for Combination Products.